HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 30986442
Brolucizumab: First Approval, PMID: 31768932
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration, PMID: 32107066
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab, PMID: 32789284
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration, PMID: 33197916
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial, PMID: 28551167
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab, PMID: 32344075
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 32574761
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER, PMID: 33207259
Brolucizumab-early real-world experience: BREW study, PMID: 32709960
Brolucizumab for macular degeneration, PMID: 32921890
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment, PMID: 33007521
Is This a 737 Max Moment for Brolucizumab?, PMID: 32505363
Brolucizumab: the road ahead, PMID: 32829303
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration, PMID: 32258827
Brolucizumab, PMID: 32105421
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world, PMID: 33082532
Brolucizumab and immunogenicity, PMID: 32251366
Brolucizumab as treatment of wet age-related maculopathy, PMID: 33332477
Pharmacoeconomic Report: Brolucizumab (Beovu): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33347111
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE), PMID: 32131127
Brolucizumab-another anti-VEGF or beyond, PMID: 32317791
Brolucizumab-key learnings from HAWK and HARRIER, PMID: 32203242
Brolucizumab (Beovu) for age-related macular degeneration, PMID: 32022789
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations, PMID: 32280811
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity, PMID: 32761135
Antibodies to watch in 2020, PMID: 31847708
Clinical Review Report: Brolucizumab (Beovu): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33301280
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD), PMID: 32132677
[Vaso-occlusive retinitis following intravitreal injection of brolucizumab], PMID: 33141333
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration, PMID: 31413539
Correction: Brolucizumab-early real-world experience: BREW study, PMID: 33323990
Brolucizumab: is extended VEGF suppression on the horizon?, PMID: 31527765
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study, PMID: 33294727
CADTH Canadian Drug Expert Committee Recommendation: Brolucizumab (Beovu — Novartis Pharmaceuticals Canada Inc.): Indication: Treatment of neovascular (wet) age-related macular degeneration (nAMD) [Internet], PMID: 33301279
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration, PMID: 33630045
Comment on: Is this a 737 Max Moment for Brolucizumab, PMID: 32948293
DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma, PMID: 32407363
Antibodies to watch in 2019, PMID: 30516432
[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy], PMID: 33555415
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System, PMID: 30566697
Innovative therapies for neovascular age-related macular degeneration, PMID: 31298960
New therapeutic targets in the treatment of age-related macular degeneration, PMID: 31787390
Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?, PMID: 33187630
Drugs for common eye disorders, PMID: 31770361
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data, PMID: 32065533
Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration, PMID: 32982165
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD, PMID: 33899632
Advanced Coats' disease treated with intravitreal brolucizumab combined with laser photocoagulation, PMID: 32671288
Emerging therapies in the management of macular edema: a review, PMID: 31448093
Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema., PMID:40500587
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review., PMID:40489855
Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain)., PMID:40473932
TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration., PMID:40466770
Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis., PMID:40456283
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study., PMID:40434532
Authors' response: "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group"., PMID:40434471
Comment on "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group"., PMID:40434470
Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience., PMID:40434468
Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes., PMID:40400877
The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis., PMID:40398452
Drug-induced Vasculitis and Choroiditis after Brolucizumab., PMID:40383437
Clinical implication of aberrant choroidal feeding artery in type 1 macular neovasculopathy., PMID:40335557
Real-world safety and efficacy of Anti-VEGF treatment in Brazil., PMID:40298749
Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD., PMID:40271423
Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes., PMID:40270623
Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy., PMID:40259096
Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration., PMID:40249498
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India., PMID:40243051
Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis., PMID:40241463
Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection., PMID:40235102
Three-year visual outcomes after brolucizumab in patients with neovascular age-related macular degeneration., PMID:40229766
Novel Resolution of Multilayered Pigment Epithelial Detachment Lamellae Following Brolucizumab Treatment-A Case Report., PMID:40224928
Molecular Dynamic Stability Study of VEGF Inhibitor in Patients with Bladder Cancer., PMID:40223853
Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases., PMID:40206271
Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1., PMID:40151914
Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series., PMID:40142183
Comparison Between Intravitreal Anti-Vascular Endothelial Growth Factor Monotherapy and Vitrectomy in Age-Related Macular Degeneration with Large Submacular Hemorrhages., PMID:40094950
Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan., PMID:40078048
Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia., PMID:40051780
Increased Risk of Retinal Vasculitis May Be Associated with Aflibercept 8 mg: A Pharmacovigilance Analysis of the FAERS Database., PMID:40048264
Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis., PMID:39994103
Budget Impact Analysis of Intravitreal Injections Used to Treat Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the Dubai Healthcare System., PMID:39978290
Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration., PMID:39962248
Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection., PMID:39959882
Faricimab efficacy in a poorly responsive case of Polypoidal Choroidal Vasculopathy (PCV): A case report., PMID:39936369
Comparative Efficacy of Brolucizumab and Aflibercept in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis., PMID:39917144
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials., PMID:39892408
Adaptive Optics Ophthalmoscopy Reveals Subclinical Arteritis and Periphlebitis After Intravitreal Brolucizumab Injection., PMID:39890100
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab., PMID:39886454
Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis., PMID:39859273
Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report., PMID:39849403
Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimab., PMID:39847181
Brolucizumab for treating neovascular age-related macular degeneration: An alternative for treatment-refractory patients., PMID:39835444
Intraocular Inflammation Following Intravitreal Faricimab Injection in Neovascular Age-Related Macular Degeneration., PMID:39830553
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema., PMID:39806501
Drugs for age-related macular degeneration., PMID:39787576
Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis., PMID:39767218
"Triple and Plan" (TriPla) regimen for long lasting new generation intravitreal anti-VEGF., PMID:39763327
Brolucizumab and Platelet Activation and Reactivity., PMID:39760267
For research use only. Not for human or drug use.
